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Abstract
Background: Dipeptidylpeptidase 4 (DPP4) inhibitors have clinical benefit in patients with type 2 diabetes mellitus
by increasing levels of glucose-lowering incretin hormones, such as glucagon-like peptide -1 (GLP-1), a peptide
with a short half life that is secreted for approximately 1 hour following a meal. Since drugs with prolonged
binding to their target have been shown to maximize pharmacodynamic effects while minimizing drug levels, we
developed a time-dependent inhibitor that has a half-life for dissociation from DPP4 close to the duration of the
first phase of GLP-1 release.
Results: Saxagliptin and its active metabolite (5-hydroxysaxagliptin) are potent inhibitors of human DPP4 with
prolonged dissociation from its active site (Ki = 1.3 nM and 2.6 nM, t1/2 = 50 and 23 minutes respectively at 37°C).
In comparison, both vildagliptin (3.5 minutes) and sitagliptin ( < 2 minutes) rapidly dissociated from DPP4 at 37°C.
Saxagliptin and 5-hydroxysaxagliptin are selective for inhibition of DPP4 versus other DPP family members and a
large panel of other proteases, and have similar potency and efficacy across multiple species.
Inhibition of plasma DPP activity is used as a biomarker in animal models and clinical trials. However, most DPP4
inhibitors are competitive with substrate and rapidly dissociate from DPP4; therefore, the type of substrate, volume
of addition and final concentration of substrate in these assays can change measured inhibition. We show that
unlike a rapidly dissociating DPP4 inhibitor, inhibition of plasma DPP activity by saxagliptin and 5-
hydroxysaxagliptin in an ex vivo assay was not dependent on substrate concentration when substrate was added
rapidly because saxagliptin and 5-hydroxysaxagliptin dissociate slowly from DPP4, once bound. We also show that
substrate concentration was important for rapidly dissociating DPP4 inhibitors.
Conclusions: Saxagliptin and its active metabolite are potent, selective inhibitors of DPP4, with prolonged
dissociation from its active site. They also demonstrate prolonged inhibition of plasma DPP4 ex vivo in animal
models, which implies that saxagliptin and 5-hydroxysaxagliptin would continue to inhibit DPP4 during rapid
increases in substrates in vivo.
Background
Diabetes is a worldwide epidemic, with the World Health
organization estimating that more than 220 million people
have diabetes worldwide http://www.who.int/mediacentre/
factsheets/fs312/en/index.html, with greater than 90% of
those having type 2 diabetes mellitus (T2DM). T2DM is
thought to develop as a combination of insulin resistance
and pancreatic b-cell failure [1]. Therefore, identification
of novel treatments that would increase pancreatic insulin
secretion while protecting pancreatic b-cells are of great
interest.
Incretin hormones, such as glucagon-like peptide-1
(GLP-1), are secreted from cells in the gastrointestinal
(GI) tract into the circulation in response to nutrient
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mechanism regulating post-prandial insulin secretion
when it is needed following meals [2]. Incretins account
for up to 60% of the post-prandial insulin secretion in
healthy individuals, but the incretin response is impaired
in T2DM [3]. Incretin effects do not lead to insulin
release per se, but potentiate the physiological release of
insulin from the pancreas in response to increases in
plasma glucose. Since GLP-1 has been shown to have
the major incretin effect on glucose homeostasis in
patients with type 2 diabetes [4], much work has been
done to understand the effects of this incretin hormone
on normal and pathophysiological glucose homeostasis.
Following its secretion, dipeptidylpeptidase-4 (DPP4)
rapidly metabolizes the intact form of GLP-1 (GLP-17-36)
to inactive GLP-19-36 with a half-life of 1 to 2 minutes in
vivo [5]. Therefore, two approaches have been taken to
increase activity of the incretin axis, parenteral adminis-
tration of DPP4-resistant GLP-1 analogues or oral
administration of DPP4 inhibitors. DPP4 inhibitors have
minimal risk of hypoglycemia because they enhance glu-
cose-dependent insulin secretion and glucagon reduction.
They are also weight neutral; i.e., they do not promote
weight gain that is typically seen with many other anti-
diabetic agents. DPP4 inhibitors are also effective in com-
bination with several other diabetes drug classes [6-8].
Finally, data from animal models indicate that GLP-1 is a
trophic factor for b-cells, and potentiating endogenous
incretins with DPP4 inhibitors does increase b-cell func-
tion and number, thereby contributing to improvement
of b-cell function over the long-term [9].
There are many examples of enzyme inhibitors display-
ing time-dependence (e.g. [10,11]), with several becoming
marketed drugs, including members of the DPP4 inhibi-
tor class [12-14]. In many cases, prolonged pharmacody-
namic effects on the target enzyme (when compared to
the pharmacokinetics of the drug) confers an advantage
over rapidly dissociating compounds, because time-
dependent drugs typically require lower plasma levels
and reduced drug peak-to-trough ratios, reducing the
risk of off-target toxicity [11,15]. In humans, peak GLP-1
secretion occurs during the first phase of secretion,
which occurs rapidly following a meal, giving a 2- to 3-
fold increase that lasts 30 to 60 minutes [3]. This can be
followed by a prolonged phase that gives a small increase
in GLP-1 levels above fasting levels for up to 2 hours
[reviewed in [16]. Therefore, we hypothesized that if a
time-dependent inhibitor has a half-life for dissociation
close to the duration of the first phase of GLP-1 secre-
tion, the majority of the enzyme-inhibitor complex
would not dissociate during the release of GLP-1 and this
would maximize the compound’s beneficial effects while
minimizing plasma drug levels. DPP4 also has many
other substrates in vitro, although only a few have been
shown to be cleaved by DPP4 in vivo (reviewed in [17]).
Therefore, it would be ideal if binding did not extend
past the duration of first phase GLP-1 secretion, such
that the inhibitor activity would follow its pharmacoki-
netics for inhibition of cleavage of other substrates of
DPP4, should any such substrates have more prolonged
in vivo half-lives relative to GLP-1.
Here we describe the inhibitory properties of saxaglip-
tin and its 5-hydroxy metabolite, which are both slow
binding DPP4 inhibitors with extended off-rates from
DPP4 at 37°C, similar to the duration of the first phase of
release of GLP-1 in vivo. We also use the ex vivo plasma
DPP assays that are used in preclinical animal models
and the clinic as a biomarker for efficacy, to demonstrate
how slow binding compounds such as saxagliptin differ
from rapidly dissociating DPP4 inhibitors. We show that
saxagliptin does not have a dilution artifact or a large
dependence on the pseudo-substrate used in the assay,
unlike rapidly dissociating DPP4 inhibitors, and we dis-
cuss the significance of these findings.
Results
Saxagliptin is a potent inhibitor of human DPP4 in vitro
irrespective of substrate
We measured the IC50 for inhibition of substrates across a
range of substrate concentrations (10 μM to 1000 μM,
dependent on substrate) that straddled the Km for the
pseudo-substrate gly-pro-pNA (Km 180 ± 8 μM, kcat 40 ±
9s
-1, room temp, n = 3), and GLP-1 (Km 24 ± 16 μM,
kcat 2.9 ± 0.9 s
-1; room temp, n = 5), then calculated the
Ki for inhibition of cleavage by each substrate (Table 1).
Each of the DPP4 inhibitors tested were equipotent
inhibitors of GLP-1 and gly-pro-pNA, as expected for
inhibitors that are competitive with substrate and bind
in the active site of DPP4. Therefore, we used gly-pro-
pNA as a substrate in subsequent experiments. Saxaglip-
tin was approximately 10-fold more potent than vilda-
gliptin or sitagliptin under these conditions at room
temperature.
Potency and selectivity of saxagliptin and 5-
hydroxysaxagliptin for human enzymes in vitro at 37°C
Routine screening was performed at room temperature.
However, as DPP4 inhibition in vivo occurs at 37°C, we
measured the potency and selectivity of DPP4 inhibitors
in vitro at that temperature (Table 2). The Km and
turnover rate of gly-pro-pNA pseudo-substrate for
DPP4 increased (Km = 209 ± 18 μM; kcat = 67 ± 4 s
-1,
n = 3), as did the Ki values for inhibition of DPP4 by
DPP4 inhibitors (Table 2). Saxagliptin was 10-fold more
potent than either vildagliptin or sitagliptin at 37°C. Sax-
agliptin generates an active metabolite in vivo [18], 5-
hydroxysaxagliptin; it was 2-fold less potent than
saxagliptin.
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DPP4 and is also cleaved by other enzymes, including
DPP8 (Km = 792 ± 60 μM; kcat = 5.1 ± 0.4 s
-1,n=3 )a n d
DPP9 (Km = 221 ± 27 μM ;k c a t=3 . 7±0 . 7s
-1,n=3 ) ,
although the cleavage rate of both enzymes is 20-fold
lower than DPP4. Therefore, we also used this substrate to
investigate inhibition of DPP8 and DPP9 by DPP4 inhibi-
tors. Saxagliptin is approximately 400-fold selective and
75-fold selective for DPP4 versus DPP8 and DPP9, respec-
tively, with the 5-hydroxymetabolite having approximately
twice the selectivity (DPP8 approximately 950-fold and
DPP9 approximately 160-fold). In comparison, vildagliptin
had 400-fold selectivity for DPP8 and 20-fold selectivity
for DPP9, while sitagliptin had 1900-fold selectivity for
DPP8 and 3000-fold selectivity for DPP9.
Saxagliptin and 5-hydroxysaxagliptin were tested against
multiple other enzymes (at room temperature). Both com-
pounds had > 1000-fold selectivity against FAP, and >
6000-fold selectivity against DPP2 and all other proteases
tested: these included neutral endopeptidase, angiotensin
converting enzyme, aminopeptidase P, prolidase, prolyl
carboxypeptidase, activated protein C, chymotrypsin, fac-
tor IXa, Factor VIIa, Factor Xa, Factor XIa, factor XIIa,
plasma kallikrein, plasmin, thrombin, tissue kallikrein, tis-
sue plasminogen activator, trypsin and urokinase (data not
shown). They also had > 10,000-fold selectivity against a
panel of 39 unrelated proteins that included 15 G-protein
coupled receptors, 4 nuclear hormone receptors, 6 ion
channels, 4 other enzymes and 10 transporters (data not
shown).
Potency and selectivity of saxagliptin and
5-hydroxysaxagliptin for inhibition of cynomolgus
monkey DPP enzymes in vitro at 37°C
The potency and selectivity for all 4 compounds for
inhibition of cynomolgus monkey (rhesus monkey has
the same DPP4 DNA sequence) DPP4, DPP8 and DPP9
is shown in Table 3 and is very similar to that found
versus the human enzymes.
Similar data were also obtained for mouse and rat
enzymes (data not shown). Therefore, we confirmed
that the potency and specificity of saxagliptin and its 5-
hydroxymetabolite were similar across species in vitro.
We did not investigate the effects of DPP4 inhibitors on
other peptidases from other species because no effect of
saxagliptin and 5-hydroxysaxagliptin were seen on the
human proteins tested.
Saxagliptin and 5-hydroxysaxagliptin are long-acting
DPP4 inhibitors in vitro
During the course of initial experiments, we noticed that
there was time dependence to inhibition of DPP4 by
some DPP4 inhibitors. In order to determine time-
dependence, we preincubated DPP4 inhibitors with
DPP4 and measured the rate of dissociation of DPP4
inhibitors from DPP4 using an ‘infinite dilution’ method.
The data in table 4 show that saxagliptin and 5-hydro-
xysaxagliptin have slow binding when tested at 37°C,
with t1/2 for dissociation of 50 minutes and 23 minutes,
respectively. While vildagliptin shows some evidence of
slow binding (t1/2 = 3.5 minutes), this was much less
pronounced. Sitagliptin showed no time dependence
(within the limitations of the experimental protocol at <
2 minutes). The time dependence was only found for
inhibition of DPP4 and was not seen during experiments
investigating the inhibition of DPP8 and DPP9; there-
fore, these prolonged effects would only relate to inhibi-
tion of cleavage of DPP4 substrates by DPP4.
Saxagliptin does not have a dilution artifact in plasma
DPP assays in vitro
The ex vivo assay measuring inhibition of plasma DPP4
activity has been used as a key biomarker assay for
DPP4 inhibitor assessment by multiple groups in both
animal models and in the clinic. Given that the duration
of the ex vivo assay is typically between 10 and 20 min-
utes, there would be no dilution artifact predicted for ex
vivo determination of inhibition from saxagliptin dosed
animals, because negligible dissociation of saxagliptin
from DPP4 would occur over the time frame of the
experiment (Table 4 and the rate of dissociation is
Table 1 Inhibition of isolated cloned human DPP4 at
room temperature
compound GLP-1 Ki (nM) gly-pro-pNA Ki (nM)
Saxagliptin 0.41 ± 0.1 (7) 0.45 ± 0.1 (5)
Sitagliptin 2.5 ± 0.7 (4) *** 8 ± 1 (5)***
Vildagliptin 1.5 ± 0.5 (4) *** 7 ± 2 (5)***
mean ± standard deviation (number of independent experiments). ***P < 0.001
versus saxagliptin
Table 2 Inhibition of isolated, cloned human DPP4, DPP8 and DPP9 at 37°C
DPP4 Ki (nM) DPP8 Ki (nM) DPP9 Ki (nM)
Saxagliptin 1.3 ± 0.3 (12) 508 ± 174 (13) 98 ± 44 (11)
5-hydroxysaxagliptin 2.6 ± 1.0 (12)*** 2495 ± 727 (14)* 423 ± 64 (12)
Vildagliptin 13 ± 2.8 (12)*** 5218 ± 2319 (14)*** 258 ± 93 (12)
Sitagliptin 18 ± 1.6 (12)*** 33780 ± 5532 (12)*** 55142 ± 19414 (11)***
mean ± standard deviation (number of independent experiments). *P < 0.05, **P < 0.01, ***P < 0.001 versus saxagliptin
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saxagliptin, we took naive human plasma and compared
samples with just the addition of compound to plasma
only, to samples where compound was added to both
plasma and buffer (such that total concentration of drug
was kept constant during the ‘dilution step’).
Saxagliptin is unaffected by the 3-fold dilution in the
human plasma assay (Figure 1a) using ala-pro-AFC as sub-
strate. However, sitagliptin clearly has a dilution artifact
(Figure 1b). When sitagliptin was added only to the
plasma, the inhibition curve shifted 3-fold to the right
compared to when compound was added to both the
plasma and the dilution buffer (IC50 = 152 ± 41 nM versus
414 ± 116 nM: mean ± s.d., n = 3), except where there is
virtually no inhibition or full inhibition, consistent with
the 3-fold dilution during substrate addition. This is pre-
sumably due to a new equilibrium being rapidly estab-
lished following dilution, such that the potency of
sitagliptin will be underestimated when compound is only
present in the plasma. Similar data were also obtained
using both cynomolgus and rhesus monkey plasma (data
not shown).
Maximum inhibition of plasma DPP4 activity in plasma
samples by DPP4 inhibitors differs between species
Untreated human plasma samples gave a plasma DPP
enzyme activity rate of 5.0 ± 0.6 nmoles/min per ml
plasma (mean ± s.d., n = 3 independent experiments)
when ala-pro-AFC was used as substrate. Untreated
cynomolgus and rhesus monkey plasma DPP4 rates were
similar to those seen in human, with rates of 5.2 ± 0.3
and 7.3 ± 0.2 nmoles/min per ml plasma, respectively.
However, the ability of DPP4 inhibitors to inhibit cleave-
age of peudo-substrates differs among species. Figure 2
shows that the maximum inhibition of plasma DPP activ-
ity seen with saxagliptin was approximately 85% in rhesus
and 80% in cynomolgus monkeys, but > 95% in humans
(Figure 2). Like human, rodent (mouse and rat) and dog
plasma DPP is inhibited > 95% by saxagliptin (data not
shown).
These effects were shown to be independent of DPP4
inhibitor and similar data were obtained with gly-pro-
pNA as the pseudo-substrate (Table 5; Figure 3). Since
the pseudo-substrates are not specific for DPP4, pre-
sumably these findings reflect a species difference in the
relative activity of all the other plasma peptidases that
cleave these pseudo-substrates.
The in vitro IC50 for inhibition of human, rhesus
monkey and cynomolgus monkey plasma DPP activity
by saxagliptin, vildagliptin and sitagliptin was similar
across species (Table 5). Therefore, although there were
different amounts of maximal inhibition among species,
DPP4 inhibitors have similar potency in rhesus monkey,
cynomolgus monkey and human plasma for inhibition
of plasma DPP activity.
Choice of assay affects the IC50 measured for inhibition of
plasma DPP activity by DPP4 inhibitors at steady-state in
vitro
The measured IC50 varies with the ratio of substrate con-
centration to substrate Km for competitive inhibitors (see
Methods). Using the assays described here, Km values
were calculated as 57 ± 13 μM (n = 3 independent experi-
ments) for the ala-pro-AFC assay, and 180 ± 10 μM( n=
3) for gly-pro-pNA assay in human plasma. Km values
were similar in cynomolgus monkey plasma, at 35 ± 6 μM
(n = 3) for ala-pro-AFC assay and 134 ± 5 μM (n = 3) for
gly-pro-pNA assay. Since the majority of DPP4 inhibitors
are competitive with substrate, a difference in substrate
concentration will affect the measured IC50 of these inhibi-
tors. In the two pseudo-substrate assays we used to mea-
sure inhibition of plasma DPP activity, the ratio of Km to
substrate concentration is approximately 7-fold in the ala-
pro-AFC assay (370 μM substrate concentration), but is
only 2-fold in the gly-pro-pNA assay (400 μMs u b s t r a t e
concentration). Therefore, using gly-pro-pNA as substrate
would give an apparent increase in potency of DPP4 inhi-
bitors compared to ala-pro-AFC. Further, the difference in
temperature (30°C versus room temperature) and pH (7.4
Table 4 On and off rates of DPP4 inhibitors at 37°C
Compound kon, 10
5 M
-1 s
-1 koff, 10
-5 s
-1 t1/2 (min.)
37°C
Saxagliptin 4.6 ± 0.6 23 ± 1 50
5-hydroxysaxagliptin 0.7 ± 0.1 50 ± 2 23
Vildagliptin 1.2 ± 0.2 330 ± 30 3.5
Sitagliptin > 100 > 580 < 2
mean ± standard error. Standard errors for kon were calculated from
equations (2), (3) and (4), and for koff are from the fits to equation (5)
Table 3 Inhibition of isolated, cloned cynomolgus monkey DPP4, DPP8 and DPP9 at 37°C
DPP4 Ki (nM) DPP8 Ki (nM) DPP9 Ki (nM)
Saxagliptin 1.1 ± 0.2 (14) 390 ± 82 (6) 61 ± 5 (6)
5-hydroxysaxagliptin 2.9 ± 1.1 (13)*** 2061 ± 658 (6)*** 323 ± 60 (6)*
Vildagliptin 6.8 ± 2.0 (14)*** 3692 ± 917 (7)*** 125 ± 39 (7)***
Sitagliptin 15.6 ± 3.6 (14)*** 21949 ± 17461 (6)*** 65757 ± 7966 (6)***
mean ± standard deviation (number of independent experiments). *P < 0.05, **P < 0.01, ***P < 0.001 versus saxagliptin
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sured IC50. Figure 3 shows the inhibition of cynomolgus
monkey plasma DPP activity in vitro for saxagliptin and
sitagliptin under pseudo-steady-state conditions. There
was a small change in IC50 for saxagliptin (2.5 ± 0.2 nM to
9.8 ± 0.3 nM, P < 0.0001), with a narrow concentration
range over which a difference would be seen between the
two assays (1 to 10 nM. Figure 3A). This presumably
reflects differences in temperature and pH between the
two assays. However, at concentrations of sitagliptin
between 5 and > 3000 nM, much more inhibition of DPP
activity is seen with the gly-pro-pNA assay than with the
ala-pro-AFC assay (Figure 3B). Further, the IC50 for inhibi-
tion in the ala-pro-AFC assay was significantly increased
26-fold compared to the gly-pro-pNA assay, from 17 ± 2
nM to 440 ± 163 nM (P < 0.0001). Similar data were
obtained using human plasma (data not shown).
Measurement of plasma DPP activity in ex vivo assays
The differences in dissociation rate from DPP4 and the
substrate used have substantial implications for mea-
surement of activity following dosing in animals and
humans. Figure 4 shows data from an in vivo study
where various doses of saxagliptin and sitagliptin were
given to cynomolgus monkeys and plasma DPP inhibi-
tion was measured after 24 hours, at trough.
When the ala-pro-AFC assay was used to measure
plasma DPP inhibition ex vivo, saxagliptin treatment
resulted in close to maximal inhibition of the inhibitable
plasma DPP activity at its highest doses, with the 1, 3
and 10 mg/kg doses being statistically different from
vehicle. However, sitagliptin treatment had no effect on
plasma DPP activity at any of the doses. When the gly-
pro-pNA assay was run on exactly the same samples,
similar results were obtained for saxagliptin and there
was no statistical difference between the data obtained
with either assay at any dose. In contrast to the ala-pro-
AFC assay, sitagliptin treatment gave statistically signifi-
cant inhibition of plasma DPP activity at 3, 10 and 40
mg/kg doses when compared to vehicle in the gly-pro-
pNA assay. Further, plasma DPP inhibition in the gly-
pro-pNA assay at the 10 and 40 mg/kg doses were sta-
tistically significantly different from those obtained
using the ala-pro-AFC assay (P = 0.07 for the 3 mg/kg
dose). However, the highest dose tested still did not give
maximal inhibition of plasmaD P Pa c t i v i t y .T h e r e f o r e ,
choice of assay had significant relevance for the inter-
pretation of inhibition by sitagliptin in this study.
Discussion
Saxagliptin (BMS-477118) is a potent inhibitor of DPP4
that is approximately 10-fold more potent than vilda-
gliptin or sitagliptin. Saxagliptin also has an active
Figure 1 The effect of dilution on the IC50 for inhibition of human plasma DPP activity by saxagliptin (Panel A) and sitagliptin (Panel
B) using ala-pro-AFC as substrate (activity is measured as arbitrary fluorescence units. Mean ± s.e.m., n = 3 independent experiments, 3
replicates per experiment).
Figure 2 Percent inhibition of plasma DPP activity in human,
rhesus monkey and cynomolgus monkey plasma by
saxagliptin using ala-pro-AFC as substrate.
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human plasma at levels between 2- and 7-fold higher
than saxagliptin (Fura 2009). 5-hydroxysaxagliptin is 2-
fold less potent than saxagliptin, but approximately 5-
fold more potent than sitagliptin and vildagliptin.
The data here shows that temperature and the choice of
substrate can have significant effects on IC50 values,
accounting for some of the differences in values typically
reported (reviewed in [17]). However, Thomas et al. [14]
reported very high IC50 values for saxagliptin and vilda-
gliptin in particular. In the case of saxagliptin, the value
was 50-fold higher than the Ki value reported here and
50-fold higher than the value reported for their DPP4 inhi-
bitor, linagliptin. Saxagliptin (Onglyza
®) is available com-
mercially in many world markets at doses of 2.5 mg and
5 mg [6] and the minimal efficacious dose of linagliptin is
5 mg [19]. It is difficult to conceive how saxagliptin could
be 50-fold less potent than linagliptin in vitro, but at least
equipotent in the clinic; therefore, it seems likely that the
data reported here are more accurate determinations of
the activity of saxagliptin and vildagliptin. A known con-
centration of pure DPP4 is typically used in the majority
of these in vitro studies (we used 100 pM of isolated
cloned human DPP4) because a low concentration of
DPP4 is important for avoiding obtaining artifactually high
inhibition values. Part of the reason for the discrepancy
may be that Thomas et al. [14] are the only group to use
“DPP4 extracted from Caco cell membranes”, with DPP4
purity and concentration undisclosed.
The increased potency and prolonged binding of saxa-
gliptin compared to sitagliptin and vildagliptin may be a
reflection of its strong interactions with both Ser
630 and
Glu
205/Glu
206, whereas sitagliptin interacts primarily with
Glu
205/Glu
206, and vildagliptin with Ser
630 [17]. Further,
we showed that saxagliptin demonstrated slow-onset
inhibition at room temperature that was partially due to
a covalent, but reversible enzyme-adduct formation at
Ser
630, but also partially due to another conformational
change induced by saxagliptin [20]. Both saxagliptin and
5-hydroxysaxagliptin also have slow binding kinetics at
37°C and would be expected to have prolonged pharma-
codynamic effects in vivo.
The data in Figure 4 shows that saxagliptin bound to
DPP4 prior to substrate addition remained bound during
the time course of the ex vivo assay. The half life for disso-
ciation of saxagliptin from DPP4 (t1/2 of 50 minutes at
37°C) is similar to the duration of first phase of elevated
GLP-1 in the plasma following a meal in humans [4]. This
may be relevant to the cleavage of endogenous substrate(s)
because saxagliptin (and 5-hydroxysaxagliptin) given
before a meal will already be bound to DPP4 at its site(s)
of action. When incretins are released in response to a
meal, incretins will increase and compete with inhibitors
with rapid off-rates. However, this would be unlikely to
Table 5 Maximum levels of inhibition of human and monkey plasma DPP activity using ala-pro-AFC as substrate
Rhesus Cyno Human
IC50 (nM) Max % inhib IC50 (nM) Max % inhib IC50 (nM) Max % inhib
saxagliptin 2.9 ± 0.3 86 ± 1
††† 2.4 ± 0.2 81 ± 6
†† 4.0 ± 0.8 100 ± 0
vildagliptin 17 ± 5** 85 ± 1
††† 13 ± 4** 79 ± 6
†† 20 ± 7* 98 ± 1
sitagliptin 17 ± 2*** 87 ± 1
††† 17 ± 2*** 80 ± 7
†† 22 ± 3*** 98 ± 0
N = 3 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 versus saxagliptin.
††P < 0.01,
†††P < 0.001 versus human
Figure 3 Inhibition of cynomolgus monkey plasma DPP activity by saxagliptin (Panel A) and sitagliptin (Panel B) using the ala-pro-
AFC and gly-pro-pNA assays (mean of 3 independent experiments).
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raised for significantly longer than the duration of the first
phase of GLP-1 secretion, when saxagliptin would equili-
brate with substrate as with the other DPP4 inhibitors. In
clinical practice, DPP4 inhibitors currently have a placebo-
like side-effect profile in trials up to 2 years in length.
Therefore, rapidly dissociating DPP4 inhibitors can be
given at high enough doses that any theoretical advantages
from extended binding are currently not seen in the clinic.
However, the chronic adverse event profiles of current
DPP4 inhibitors are not yet fully defined and differences
between DPP4 inhibitors may yet be seen.
Saxagliptin and 5-hydroxysaxagliptin are selective for
DPP4 versus DPP8 and DPP9 at 37°C. Neither saxaglip-
tin nor 5-hydroxysaxagliptin exhibited slow binding
kinetics to DPP8 or DPP9, so any DPP8/9 related phar-
macodynamics would closely match their pharmacoki-
netics. The potential for inhibition of DPP8 and DPP9
in vivo is difficult to assess in the absence of a known
physiologically relevant substrate and knowledge of the
specific tissues and cells where either may play a physio-
logical role. Further, as DPP8 and DPP9 are cytosolic
enzymes [21], the cytosolic concentration of saxagliptin
and 5-hydroxysaxagliptin in those cells would also be
required to accurately predict the potential for inhibi-
tion. Since this information is unknown (and to test for
other off-target issues), extensive toxicity studies are
typically undertaken in several species and adverse
events are scrutinized in clinical studies. As discussed
previously (reviewed in [17]), the preponderance of evi-
dence for saxagliptin would show that there is no toxi-
city attributable to inhibition of DPP8 or DPP9 at
clinically relevant doses across species.
There was no significant species difference for potency
of inhibition of human and cynomolgus monkey DPP4,
DPP8, DPP9 or plasma DPP activity for three DPP4 inhi-
bitors (saxagliptin, vildagliptin or sitagliptin). However,
there were significant differences in the maximum
amount of inhibition of plasma DPP activity seen
between rhesus and cynomolgus monkey plasma (80 to
85%) and the other species tested (95%). This presumably
shows a difference between the levels of dipeptidylpepti-
dases found in the plasma of the two species. The identi-
ties of the peptidases that underlie this difference are
unknown and were not a focus of these experiments.
However, as there was no differentiation between saxa-
gliptin, vildagliptin and sitagliptin, it is unlikely to be
attributable to species differences in DPP8 or DPP9
expression (also consistent with current understanding
that DPP8 and DPP9 are not secreted or thought to be
present in plasma [17]).
Based on the data presented here, interpretation of
data from ex vivo assays for DPP4 inhibitors should be
done with caution because the choice of substrate, as
well as the nature of the ex vivo assay (such as dilution
artifact), can all affect measured efficacy. The difference
in plasma DPP inhibition for sitagliptin between these
two assays (Figure 4) can be explained by sitagliptin’s
Figure 4 The effect of pseudo-substrate choice on the measurement of plasma DPP activity ex vivo in cynomolgus monkeys 24 hours
post dose. **P < 0.01, ***P < 0.001 versus vehicle.
†P < 0.05,
††P < 0.01, versus ala-pro-AFC at the same dose. The dashed line represents the
average maximum inhibition seen (68.9 ± 3.9%, 1 hour post dose at the highest doses tested).
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of DPP4. Due to the difference in the ratio of Km to
substrate concentration between the two assays, one
substrate is less effective at competing out the inhibitor
and the inhibitor appears more potent in that assay.
Consistent with this conclusion was the in vitro data
that showed that this issue would most likely manifest
itself across the range of plasma concentrations typically
found at trough (24-hour post dose) for sitagliptin in
cynomolgus monkeys. In contrast, saxagliptin would not
d i s s o c i a t ea p p r e c i a b l yf r o mt h ea c t i v es i t ed u r i n gt h e
time course of the assay and there would be no inhibi-
tor-substrate competition.
Krishna et al. [22] recently illustrated the benefits of
accelerating drug development using biomarkers with
the example of DPP4 inhibitors and the plasma DPP4
assay. While this approach can be fundamentally useful,
some important caveats to this approach have been
demonstrated here. The pseudo-substrate gly-pro-pNA
was used in both clinical assays to determine plasma
DPP inhibition for saxagliptin and sitagliptin. However,
the conditions are very different: i.e. the substrate con-
centration is 2000 μM (10-fold the Km), with an 11-fold
dilution step and 120 minute assay duration in the saxa-
gliptin assay [23]; the substrate concentration is 400 μM
(2-fold Km), with a 2.5-fold dilution step and a 14 min-
ute assay duration in the sitagliptin assay [24]. The data
presented here show that, given the comparably longer
duration of the assay, the larger dilution factor and the
higher substrate concentration in the saxagliptin clinical
assay, it is not possible to perform a meaningful direct
comparison between clinical data for the two drugs
using these different assays. This may explain why
Krishna et al. [22] reported that they need 80% inhibi-
tion of plasma DPP4 activity at trough (24-hours post
dose) to obtain maximal glucose lowering for sitagliptin.
However, only 50% to 60% inhibition of plasma DPP
activity was seen 24-hours post dose for vildagliptin at
the 100 mg dose [25] and for saxagliptin at the 5 mg
dose [23]. Despite these differences, all the DPP4 inhibi-
tors have similar glucose-lowering efficacy in the clinic
at those doses, leading Neumiller et al. [6] to conclude
that “there does not appear to be a compelling advan-
tage of one DPP-4 inhibitor over another”.
Further, saxagliptin is localized to the GI tract when
given intra-arterially in animal models [18]. Holst and
Deacon [26] proposed that GLP-1 cleavage in the GI tract
is important: therefore, saxagliptin, by virtue of its location
in the GI tract, may give rise to total inhibition of GLP-1
cleavage, while cleavage of another substrate in a different
tissue could be unaffected, and the ex vivo plasma DPP
assay shows only partial inhibition of DPP4. Further, the
tissue distribution of all DPP4 inhibitors is unlikely to be
the same and different DPP4 inhibitors may have different
effects if there is tissue-specific localization of inhibitor or
substrate. Thus, the action of a DPP4 inhibitor in the rele-
vant tissue can only be approximated by the evaluation of
ex vivo plasma DPP activity.
Conclusions
Saxagliptin and its active metabolite are potent, selective
inhibitors of DPP4, with prolonged dissociation from its
active site. They also demonstrate prolonged inhibition of
plasma DPP4 ex vivo in animal models, which implies that
saxagliptin and 5-hydroxysaxagliptin would continue to
inhibit DPP4 during rapid increases in endogenous sub-
strates (such as GLP-1 during its physiologic release).
However, this remains to be demonstrated for a physiolo-
gic substrate in vivo.
Interpretation of data from ex vivo assays for DPP4 inhi-
bitors should be done with caution because the choice of
substrate, as well as the nature of the ex vivo assay (such
as dilution artifact), can all affect measured efficacy.
Therefore, while ex vivo plasma DPP assays may be useful
as a biomarker for a compound, for the reasons discussed
in this paper, clinically relevant efficacy, efficacy for endo-
genous substrates, or relative efficacy across DPP4 inhibi-
tors cannot be predicted solely using a plasma DPP
activity assay.
Methods
Reagents
Saxagliptin (Onglyza
©, BMS-477118, or (1 S,3 S,5 S)-2-[(2
S)-2-Amino-2-(3-hydroxytricyclo[3.3.1.1
3,7]dec-1-yl)
acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, monohy-
drate [13], vildagliptin [27], sitagliptin [28], active and
DPP4 cleaved glucagon-like-peptide-1 (GLP-17-36 and
GLP-19-36, respectively) were synthesized at Bristol-Myers
Squibb. All other chemicals were reagent grade, obtained
from Sigma (St Louis, MO). For the in vitro assays, plasma
from rhesus and cynomolgus monkeys was obtained fro-
zen from Bioreclamation Inc. (Hicksville, NY). Plasma
from human blood was obtained from healthy volunteers
within BMS (after obtaining written consent, following the
BMS standard operating procedure RD-DIR-003, in accor-
dance with the Helsinki Declaration) by collecting blood
into EDTA tubes. These tubes were kept on ice and were
centrifuged at 3000 rpm, 4°C for 15 minutes (within 15
minutes of collection). Plasma was aliquoted into polypro-
pylene tubes, quick-frozen in powdered dry ice, and stored
at -80°C until the assay was performed.
Steady-state inhibition of isolated cloned human and
cynomolgus monkey DPP4, 8 and 9 in vitro at 37°C
All solutions were preheated to 37°C. Inhibitors were
preincubated with enzyme for 40 minutes prior to assay
initiation. The assay was initiated by substrate addition
and contained: 100 mM Aces, 52 mM Tris, 52 mM
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at either 120 μM or 1000 μM), inhibitor (various con-
centrations) and 1% DMSO (final volume of 100 μl).
Production of p-nitroaniline was measured at 405 nm at
30 second intervals over 40 minutes using a Spectramax
340 plate reader (Molecular Probes, Carlsbad, CA). Soft-
max Pro software from Molecular Devices (Sunnyvale,
CA) was used to obtain the initial slope of the reaction
in each well, and the fits were inspected to insure that
the reactions were linear to a correlation coefficient of
0.99. An Excel template with XLFit (IDBS, Guildford, U.
K.) was used for determination of the IC50 for inhibition
at each substrate concentration. Three models of
enzyme inhibition (competitive, uncompetitive, and
non-competitive) were used, but all of the inhibitors in
our DPP4 program yielded competitive inhibition
against gly-pro-pNA. Therefore, IC50 was then con-
verted to Ki assuming competitive inhibition according
to:
Ki = IC50 
1+ S
Km
 (1)
The calculated Ki values for competitive inhibition at
each substrate concentration were averaged and
reported. DPP8 and DPP9 were tested under identical
conditions. The in vitro assays were also used to deter-
mine substrate Km, by varying substrate concentration
across an appropriate range. Km was calculated using
GraFit software (Erithacus, Surrey U.K.)
Slow binding kinetics at 37°C for human DPP4
All solutions were preheated to 37°C and the assay was
run at 37°C. When slow onset inhibition occurs, final
Ki* is a function of the koff and kon (Ki* = koff/kon).
Progress of DPP4 inhibition was measured under
steady-state conditions (E < < I/(1 + S/Km)), initiating
the reaction by adding the enzyme to the substrate and
inhibitor mixture. Progress curve analysis was performed
as described previously [11] to derive kobs values:
P = vst +
(vi−vs)
kobs

1 − exp(−kobst

(2)
where P is reaction product, vi and vs are initial and
steady-state velocities, respectively, and kobs is the
pseudo-first order rate constant for the approach to
steady-state. These values were subsequently used to
generate kon,k off and final equilibrium Ki*. In the cases
where kobs was linearly dependent upon I/(1 + S/Km),
kon and koff were calculated from the slope and intercept
of the line:
kobs = konI/

1+S/Km

+ koff (3)
When kobs dependence on effective inhibitor concen-
tration was hyperbolic, kon and koff
E + I
k1

k2
EI
k3

k4
E ∗ I
were calculated using following equation according to
Scheme 1:
kobs =
k3I
Ki

1+ S
Km

+I
+ k4 (4)
where Ki is k2/k1,k on =k 3/Ki, k4 is koff and final Ki* =
koff/kon.
We measured the inhibitor dissociation constant inde-
pendently using dilution experiments because calculating
the inhibitor dissociation constant from the final complex
(k4) is subject to large errors,. Briefly, enzyme (20 nM)
and inhibitor (500 nM) were preincubated for 30 minutes
at 37°C to allow complete equilibration, then put through
a spin column P-30 (BioRad, Hercules, CA) to eliminate
excess free inhibitor. The resulting solution was immedi-
ately diluted (~ 10-fold) into an activity assay containing
an excess of substrate (250 μM, Km = 60 μM). koff was
then calculated by fitting thes u b s e q u e n tt i m ec o u r s e
with the equation:
P = vst +
(vi−vs)
koff

1 − exp(−kofft

(5)
Inhibition of DPP4 cleavage of active GLP-1 by
human DPP4
An LC/MS/MS assay was used to measure GLP-1 clea-
v a g ei nv i t r oa tr o o mt e m p e r a t u r e .T ol i m i tl o s s e so f
cleaved GLP-1 (GLP-19-36) due to aggregation and/or
adsorption to the walls of the vial, samples were diluted to
40% acetonitrile composition. To determine Km, various
concentrations of active GLP-1 (GLP-17-36; concentration
range 10 to 240 μM) were incubated with DPP4 (2 nM) in
20 mM phosphate buffer, pH 7.4. Total reaction volume
was 125 μl. Every 5 minutes, 28 μl samples were with-
drawn and quenched with 28 μl stop buffer (80% acetoni-
trile, 18% water, 2% formic acid). To determine Ki, two
concentrations of active GLP-1 (10 and 50 μM) were incu-
bated with DPP4 (0.45 nM) in 20 mM phosphate buffer,
pH 7.4. Total reaction volume was 40 μl. After 90 min,
40 μl stop buffer was added to quench the reaction.
A Thermo Fisher LTQ Orbitrap mass spectrometer in
positive electrospray mode was used to detect GLP-1 9-36.
The chromatography system was a Waters Acquity UPLC
with a Waters UPLC BEH C18, 1.7 μm, 2.1 × 50 mm col-
umn. A short gradient was employed (0% B to 100% B in
4 minutes) using 98/2 water/acetonitrile (10 mM ammo-
nium acetate) as solvent A and 2/98 water/acetonitrile
(10 mM ammonium acetate) as solvent B. A flow rate of
0.8 ml/min was used and 5 μl were injected onto the
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graphically separated from GLP-17-36. GLP-19-36 quantita-
tion was performed by integrating the sum of the 2+, 3+
and 4+ charged ions. Concentrations of GLP-19-36 were
calculated from a 1/x
2 quadratic fit calibration curve (10
nM - 2,000 nM).
Cynomolgus monkey ex vivo plasma DPP inhibition assay
Male and female cynomolgus monkeys (Charles River
BRF, Houston, TX), were housed in an AAALAC-accre-
dited facility (on a 12-hour light/dark cycle) in stainless-
steel cages. They had access to purified tap water ad
libitum and were fed Harlan Diet 2050 C (Certified 20%
protein primate diet). Six monkeys per dose group (3 to
4 males and 2 to 3 females per group) were adminis-
tered single oral gavage doses of saxagliptin (0.1, 0.3, 1,
3, or 10 mg/kg), sitagliptin (0.3, 1, 3, 10, or 40 mg/kg),
or vehicle alone (water, final pH 5.0) at a dose volume
of 2 mL/kg. Doses were administered once weekly using
a crossover design such that no monkeys received the
same dose twice. For the ex vivo cynomolgus monkey
assays, blood samples (approximately 0.5 ml) were col-
lected prior to dosing and 1, 2, 4, 6, 8, and 24 hours
post dosing in tubes containing K2EDTA. Tubes were
inverted several times to ensure mixing, and placed on
ice. Samples were centrifuged at 5000 rpm for 10 min-
utes at 4°C for plasma isolation. Plasma was stored at
-20°C until analyzed for DPP activity. No difference in
DPP inhibition was noted between males and females
and so data were combined for analyses.
Ala-pro-AFC plasma DPP inhibition assay
For the ex vivo assays, plasma from cynomolgus monkeys
was diluted with buffer alone. For the in vitro assays,
plasma ‘spiked’ with compound to be tested (10 μl) was
added to buffer alone or buffer with drug ‘spiked’ at con-
centrations that would yield the same concentration as
the ‘spiked’ plasma in the well (10 μl), followed by the
substrate (10 μl, final concentrations were ala-pro-AFC
370 μM and DMSO 3%). This procedure produced a
3-fold dilution of plasma. The buffer contained (final
concentration) 33 mM HEPES and 140 mM NaCl (no
BSA) at pH 7.9, and the assay was run at room tempera-
ture (22°C). A 384-well microplate format was employed
to measure plasma dipeptidyl peptidase activity. Activity,
the rate of release of fluorescence from the pseudo-sub-
strate, was assayed using a Fluoroskan Ascent microplate
reader with rate-determining software. Readings were
taken after a 10 second shaking step, at 405 nm excita-
tion and 510 nm emission, with subsequent reads every 1
minute for 18 minutes. Rates were determined from the
slope of the regression line fitted to the linear portion of
the data (a minimum of 8 minutes and a maximum of
12 minutes from the start of the experiment) showing the
increase in fluorescence due to cleavage of substrate over
time. Results were expressed as arbitrary units because
standard AFC curves were not run for all experiments.
The extent of DPP inhibition, derived from the reduction
in the initial rate observed at each drug concentration
with respect to untreated plasma, were determined and
IC50 values were calculated using XLfit.
Gly-pro-pNA Plasma DPP inhibition assay
This assay was reported by Merck as used in their clin-
ical trials [24], using gly-pro-pNA as substrate. The
buffer contained 100 mM HEPES with 0.1 mg/ml BSA
and the assay was run at 30°C in 96-well microplate
format (Costar 9017, Corning. Corning, NY). For the
ex vivo assays, plasma from cynomolgus monkeys was
diluted with buffer alone. For the in vitro assays,
‘spiked’ plasma (40 μl) was added to buffer alone or
buffer with drug ‘spiked’ at concentrations that would
yield the same concentration as the ‘spiked’ plasma in
the well (40 μl), followed by the substrate (20 μl, final
concentration of gly-pro-pNA is 400 μM). Activity, the
rate of release of free pNA from the pseudo-substrate,
was assayed at 30°C, using a Spectramax 340 plate
reader (Molecular Probes) with rate determining soft-
ware. Absorbance at 390 nm was measured. Results
were expressed as arbitrary units because standard
pNA curves were not run for all experiments. The
extent of DPP inhibition and IC50 values were calcu-
lated as described above.
Statistical analysis
The SAS JMP statistical package was used for all statisti-
cal analyses. A Dunnett’s test was used for comparison
to vehicle and all pairs were compared with a Tukey
HSD.
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